SPPL2C and interstitial lung disease: Contrary to the discovery cohort, MAPT rs1981997 (OR = 0.79; CI 95 % 0.68 to 0.91; p value = 0.002) and SPPL2C rs17690703 (OR = 0.64; CI 95 % 0.49 to 0.83; p value = 0.001) were associated with SSc susceptibility but not with ILD severity in the replication cohort (Table 6).